Get Antibody-Drug Conjugates: Fundamentals, Drug Development, PDF

By Kenneth J. Olivier Jr., Sara A. Hurvitz

ISBN-10: 1119060680

ISBN-13: 9781119060680

Providing useful and confirmed suggestions for antibody-drug conjugate (ADC) drug discovery luck in oncology, this ebook is helping readers enhance the drug protection and healing efficacy of ADCs to kill distinctive tumor cells.

• Discusses the fundamentals, drug supply techniques, pharmacology and toxicology, and regulatory approval strategies
• Covers the behavior and layout of oncology scientific trials and using ADCs for tumor imaging
• Includes case reviews of ADCs in oncology drug development
• Features contributions from highly-regarded specialists at the frontlines of ADC examine and development

Show description

Read Online or Download Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer PDF

Similar industrial & technical books

Read e-book online Process and Plant Safety PDF

Injuries in technical installations are random occasions. consequently they can't be absolutely kept away from. basically the chance in their prevalence should be lowered and their effects be mitigated. The publication proceeds from dangers as a result of fabrics and method stipulations to indicating technical and organizational measures for attaining the ambitions of aid and mitigation.

Download PDF by Bireswar Banerjee: Tyre retreading

The aim of this booklet is to supply information of the several elastomers - together with reclaim rubber and crumb rubbers - utilised within the rubber compounds utilized in the manufacture of other different types of tyre retreading. There are discussions approximately reinforcing fillers and different compounding constituents, their efficacy, using bonding brokers, and their relevance to the tyre retreading approach.

Renewable resources and renewable energy : a global - download pdf or read online

As power calls for proceed to surge around the globe, the necessity for effective and environmentally impartial strength creation turns into more and more obvious. In its first version, this ebook offered a well-rounded point of view at the improvement of bio-based feedstocks, biodegradable plastics, hydrogen strength, gas cells, and different features with regards to renewable assets and sustainable strength creation.

Extra info for Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer

Example text

3 mg/kg (squares), which are equivalent to 24 ± 3, 49 ± 2, and 98 ± 4 µg/kg conjugated maytansinoid, respectively. 0 mg/kg (90 µg/kg conjugated maytansinoid). The effect of weekly administration of IMGN853 on the antitumor activity against KB xenograft tumors is shown in (c). 8 mg/kg antibody) on day 6 postinoculation (open triangles), or with multiple injections (qw × 3) on day 7, 14, and 21 postinoculation (solid circles). , Molecular Cancer Therapeutics, 14(7); 1605–1613, copyright 2015, American Association for Cancer Research [22].

Gemtuzumab ozogamicin and inotuzumab ozogamicin are conjugates of a calicheamicin payload where the linker includes an acid-labile hydrazone moiety (shaded gray), and also contains a hindered disulfide bond cleavable by reduction (average DAR of these ADCs are in the range of 2 to 4 – only one linker-payload structure drawn for simplicity). The two maytansinoid ADCs show examples of conjugates with either a non-cleavable link created by reaction of the sulfhydryl group of the maytansinoid DM1 with the maleimido group of the linker (thioether bond so formed is shaded gray), as in ado-trastuzumab emtansine, or with a hindered disulfide-containing link (disulfide shaded gray) that is cleavable by reduction, as in mirvetuximab soravtansine (values for n and m are between 3 and 4 maytansinoids per antibody).

New York: Humana Press; 2013. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–60. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta‐analysis of individual patient data from randomised controlled trials. Lancet Oncology 2014;15:986–96. O’Hear C, Rubnitz JE.

Download PDF sample

Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer by Kenneth J. Olivier Jr., Sara A. Hurvitz

by David

Rated 4.96 of 5 – based on 34 votes